References
- Braunstein GD. Androgen insufficiency in women: summary of critical issues. Fertil Steril 2002;77:S94–S99.
- Liu CH, Laughlin GA, Fischer UG, Yen SSC. Marked attenuation of ultradian and circadian rhythms of dehydro-epiandrosterone in postmenopausal women: evidence for a reduced 17,20 desmolase enzymatic activity. J Clin End-rocrinol Metab 1990;71:900–906.
- Mortola JF, Yen SSC. The effects of oral dehydroepiandros-terone on endocrine-metabolic parameters in postmeno-pausal women. J Clin Endocrinol Metab 1990;71:696–704.
- Baulieu EE. Dehydroepiandrosterone: a fountain of youth? J Clin Endocrinol Metab 1996;81:3147–3151.
- Genazzani AR, Petraglia F, Bernardi F, et al. Circulating levels of allopregnanolone in humans: gender, age and endo-crine influences. J Clin Endocrinol Metab 1998;83:2099–2103.
- Mellon SH. Neurosteroids: action and clinical relevance. J Clin Endocrinol Metab 1994;78:1003–1008.
- Melcangi RC, Azcoitia I, Ballabio M, et al. Neuroactive steroids influence peripheral myelination: a promising oppor-tunity for preventing or treating age-dependent dysfunctions of peripheral nerves. Prog Neurobiol 2003;71:57–66.
- Kraemer RR, Synovitz LB, Gimpel T, Kraemer GR, Johnson LG, Castracane VD. Effect of estrogen on serum DHEA in younger and older women and the relationship of DHEA to adiposity and gender. Metabolism 2001;50:488–493.
- Casson PR, Elkind-Hirsch KE, Buster JE, Hornsby PJ, Carson SA, Snabes MC. Effect of postmenopausal estrogen replace-ment on circulating androgens. Obstet Gynecol 1997;90:995–998.
- Bernardi F, Pieri M, Stomati M, et al. Effect of different hormonal replacement therapies on circulating allogpregna-nolone and dehydroepiandrosterone levels in postmeno-pausal women. Gynecol Endrocrinol 2003;17:65–77.
- Moore R. Livial: a review of clinical studies. Br J Obstet Gynaecol 2001;106(Suppl 19):1–21.
- Genazzani AR, Petraglia F, Facchinetti F. Effects of Org OD 14 on pituitary and peripheral beta-endorphin in castrated rats and postmenopausal women. Maturitas 1987;S1:35–48.
- Genazzani AR, Bernardi F, Stomati M, et al. Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats. Neuroendocrinology 2000;72:162–170.
- Yokoi H, Tsuruo Y, Miyamoto T, Ishimura K. Steroid 5 alpha-reductase type 1 immunolocalized in the adrenal gland of normal, gonadectomized, and sex hormone-supplemented rats. Histochem Cell Biol 1998;109:127–134.
- Penning TM. 3 Alpha-hydroxysteroid dehydrogenase: three dimensional structure and gene regulation. J Endocrinol 1996;150:S175–5187.
- Cheng YJ, Karavolas HJ. Conversion of progesterone to 5a-pregnane-3,20-dione and 3a-hydroxy-5a-pregnan-20-one by rat medial basal hypothalamus and the effects of estradiol and stage of estrus cycle on the conversion. Endocrinology 1993;93:1157–1162.
- de Gooyer ME, Kleyn GT, Smits KC, Ederveen AG, Verheul HA, Kloosterboer HJ. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endrocrinol 2001;183:55–62.
- de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interac-tions of tibolone. Steroids 2003;68:21–30.
- de Wit H, Scmitt L, Purdy R, Hauger R. Effects of acute progesterone administration in healthy menopausal women and normally-cycling women. Psychoneuroendocrinology 2001;26:697–710.
- Abdalla HI, Hart DM, Lindsay R, Beastall GH. Organon OD 14 (tibolone) and menopausal dynamic hormone profiles. Maturitas 1986;8:81–85.
- Kicovic PM, Cortes-Prieto J. Luisi M, Milojevic S, Franci F. Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduction 1982;6: 81–91.
- Doren M, Rubig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindron acetate replacement therapy. Fertil Steril 2001;75:554–559.
- Erel CT, Elter K, Akman C, et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998;69:870–875.